Influence of the Alu-Repeat I/D Polymorphism in t-PA Gene Intron 8 on the Stimulated t-PA Release After Venous Occlusion

Tissue type plasminogen activator (t-PA) is released from endothelium in both a constitutive and regulated fashion. In healthy subjects, an association between net t-PA release rate and a few t-PA gene polymorphisms, including the Alu-repeat I/D polymorphism in intron 8, was described. The possible...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical and applied thrombosis/hemostasis 2003-01, Vol.9 (1), p.63-69
Hauptverfasser: Sartori, Maria Teresa, Saggiorato, Graziella, Spiezia, Luca, Varvarikis, Costantino, Carraro, Gianni, Patrassi, Giovanni Maurizio, Girolami, Antonio
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Tissue type plasminogen activator (t-PA) is released from endothelium in both a constitutive and regulated fashion. In healthy subjects, an association between net t-PA release rate and a few t-PA gene polymorphisms, including the Alu-repeat I/D polymorphism in intron 8, was described. The possible influence of the Alu-repeat polymorphism on t-PA release was evaluated after a venous occlusion test (VO) in 82 patients showing an impaired fibrinolytic capacity associated with different arterial disease or with previous venous thrombosis, and in 50 healthy controls. Euglobulin lysis time, t-PA antigen (t-PA:Ag) and activity, PAI-1 antigen and activity plasma levels were assayed before and 20 minutes after VO; the Alurepeat I/D polymorphism was determined by PCR. Defective fibrinolysis was due to reduced t-PA release in 40 patients (t-PA group) and to PAI-1 excess in 42 patients (PAI group). No differences in both genotype distribution and allele frequencies were observed between patients and controls. The t-PA:Ag increase after VO (20/0-minute levels ratio adjusted for hematocrit) was considerably higher both in controls and in PAI group patients carrying the I allele than in the DD genotype carriers (II, ID, DD: 3.77∓0.62, 3.43∓0.44, 2.06∓0.32 in controls, and 3.67∓0.23, 2.80∓0.50, 1.62∓0.29 in PAI group, respectively). The difference was significant between the DD and both the ID and II genotypes in controls (p
ISSN:1076-0296
1938-2723
DOI:10.1177/107602960300900109